Sio Capital Management, LLC

Sio Capital Management, LLC is a New York-based hedge fund specializing in healthcare and life sciences investing through a long/short equity strategy. The firm files 13F reports with the SEC under CIK #0001482416, maintaining an extensive disclosure history spanning over a decade that provides exceptional visibility into the firm's healthcare-focused investment approach through multiple market cycles and industry transformations. Founded by Michael Castor, MD, Sio Capital brings differentiated expertise to healthcare investing through the combination of medical training, scientific rigor, and financial acumen. The firm's name—"Sio"—derives from scientific nomenclature, reflecting the technical foundation underlying the investment approach. Castor's background as a physician and former healthcare analyst at prominent investment firms established the analytical framework distinguishing Sio's fundamental research from generalist investors attempting healthcare exposure. Operating from New York positions Sio Capital within proximity to major pharmaceutical and biotechnology company headquarters, academic medical centers, and the institutional investor community that allocates to healthcare-specialist managers. The concentration of healthcare investment expertise in New York and Boston creates collaborative and competitive dynamics that sharpen analytical capabilities for firms operating within these ecosystems. The extended 13F filing history under CIK #0001482416, dating to 2010, provides one of the more comprehensive healthcare-specialist disclosure records available. This longitudinal dataset spans multiple biotech cycles, patent cliffs, regulatory regime changes, and transformative developments including immuno-oncology emergence and COVID-19 pandemic impacts on the healthcare sector.

Sio Capital Management employs a fundamentally-driven, long/short equity strategy focused exclusively on healthcare and life sciences investments. The firm's approach combines deep scientific analysis with rigorous financial assessment, seeking to generate alpha through superior understanding of clinical data, regulatory pathways, and commercial dynamics that determine healthcare company outcomes. The investment process leverages specialized expertise across healthcare subsectors including biotechnology, pharmaceuticals, medical devices, healthcare services, and life sciences tools. Security selection requires evaluation of complex scientific data—clinical trial results, FDA regulatory decisions, competitive pipeline dynamics—alongside traditional financial analysis. This dual competency requirement creates barriers to entry that limit competition from generalist investors lacking scientific training. The long/short structure enables Sio to express both positive and negative views across the healthcare universe. Short positions targeting overvalued or scientifically challenged companies provide hedging and alpha generation opportunities alongside long positions in undervalued or underappreciated healthcare opportunities. The Sector Allocation History observable through extensive 13F filings reveals positioning patterns across healthcare subsectors—biotechnology, large pharmaceuticals, medical devices, healthcare services—as relative opportunities shift. The Top 10 Holdings Concentration provides insight into conviction levels among the firm's largest positions. Healthcare specialist managers often maintain meaningful positions in highest-conviction ideas where scientific and commercial analysis provides differentiated insight, accepting concentration risk in exchange for alpha potential. Turnover characteristics trend toward moderate to higher levels, reflecting healthcare sector dynamics where clinical trial results, FDA decisions, and competitive developments can rapidly alter position attractiveness. Active management responds to scientific and regulatory catalysts that create information-driven trading opportunities.

Sio Capital Management, LLC presents an exceptional Historical Track Record visible through SEC filings under CIK #0001482416, spanning over a decade of healthcare-focused long/short investing through multiple complete sector cycles. This extensive longitudinal dataset enables robust analysis of investment philosophy consistency and performance characteristics across dramatically varying healthcare market environments. The Annualized Return (CAGR) derived from disclosed holdings provides statistically meaningful insight into long-term compounding behavior given the extended observation window. The decade-plus record captures sufficient sector variability—including biotechnology booms and busts, regulatory regime changes, and pandemic impacts—to assess sustainable performance characteristics. The Sharpe Ratio contextualizes returns against accepted volatility, offering risk-adjusted perspective across complete healthcare sector cycles. The sector-specialist approach should demonstrate alpha generation from scientific expertise translating into superior security selection, distinguishing performance from healthcare index returns achievable through passive exposure. The 13F Portfolio Composition across ten-plus years illuminates how Sio navigates changing healthcare dynamics—subsector rotation as opportunities shift, positioning through clinical catalysts, and adaptation to regulatory and competitive developments. The longitudinal perspective reveals investment philosophy implementation across varied sector environments. Key analytical dimensions for Sio Capital include subsector allocation patterns (biotechnology vs. pharmaceuticals vs. devices vs. services), position sizing around clinical catalysts, and conviction persistence through sector volatility. The founder's medical training and extended track record establish expectations for differentiated healthcare analysis. Given Sio Capital's decade-plus healthcare specialist track record and physician-founded investment approach, how has the Sector Allocation History evolved through multiple biotechnology cycles, and what current subsector positioning signals the firm's view on relative opportunity across the healthcare landscape following the extended biotech bear market?

Sio Capital Management's healthcare-focused long/short strategy produces a sector-concentrated risk profile with characteristics distinct from diversified equity approaches. The exclusive healthcare focus introduces sector-specific volatility while the long/short structure provides hedging capabilities that can moderate net exposure during challenging periods. The Volatility Profile for healthcare-specialist strategies reflects the sector's inherent dynamics—binary clinical trial outcomes, regulatory decisions creating step-function price movements, and patent cliff pressures producing elevated company-specific volatility. Biotechnology positions, likely prominent in the portfolio, demonstrate particularly high volatility as clinical stage companies rise or fall based on trial data. The Max Drawdown Depth analysis across Sio's decade-plus 13F history provides exceptional insight into downside behavior through multiple healthcare sector cycles. The extended record encompasses biotech selloffs in 2015-2016, drug pricing political pressures, the 2020 COVID-related market disruption, and the 2021-2022 biotechnology bear market that severely tested healthcare-focused managers. Healthcare investing introduces risks beyond traditional market exposure. Clinical trial failures can produce overnight losses of 50% or more in individual positions. Regulatory setbacks, pricing pressures, and competitive developments create binary outcomes that diversified sector allocation cannot fully hedge. The long/short structure provides some protection, but healthcare-specialist managers remain exposed to sector-wide sentiment shifts affecting both longs and shorts simultaneously. The Downside Capture Ratio derived from extensive historical holdings provides robust quantitative context for understanding how the long/short structure and position management translate into drawdown mitigation during healthcare sector corrections.